Targeting Non-Catalytic Sites of SRC Sensitizes the Efficacy of SRC Kinase Inhibitors in Solid Tumors
Yu, J.; Wang, X.; Liu, P.; Wang, Z.; Liu, J.; Gan, T.; Xu, N.; Zhou, J.; Yu, J.; Yuan, H.; Ban, X.; Liu, Y.; Zhang, X.; Li, P.; Cui, B.
Show abstract
The non-catalytic functions of kinases have provided novel and crucial mechanisms underlying kinase inhibitor resistance, thereby presenting new opportunities for discovery of kinase-targeted drugs. Nevertheless, only a very limited modulators targeting non-catalytic functions have been reported. As the first discovered proto-oncogene, the non-receptor tyrosine kinase SRC promotes the progression of hematologic malignancies and numerous solid tumors via complex pathways. Several SRC kinase inhibitors were approved for the treatment of hematologic malignancies, yet not for solid tumors. The rapid development of resistance, attributed to the complexity of the signaling pathway, is a key factor restricting the application of SRC kinase inhibitors. The non-kinase function of SRC is one of the primary reasons, but the non-kinase function of SRC remains unclear. In this study, it was discovered that upon abrogation of phosphorylation by SRC kinase inhibitors, non-catalytic SRC promotes the transcription of the oncogenes TRIB3 and SPC24 transcription by binding to their promoter sequence. Simultaneously, it interacts with TRIB3 and mutually prevents the proteasome-mediated degradation by the E3 ligase CHIP, ultimately inducing resistance to SRC kinase inhibitors. The peptide TS1-2 inhibits the tumor progression of pancreatic ductal adenocarcinoma (PDAC), kidney renal papillary cell carcinoma (KIRP), kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), and breast invasive carcinoma (BRCA), and enhances the efficacy of SRC kinase inhibitors in solid tumors. This study elucidates the mechanism of non-catalytic functions of SRC, validates the tumor-promoting function and mechanism of nuclear accumulation of SRC/TRIB3 following SRC kinase inhibitor treatment, identifies a potential target SRC/TRIB3, and offers the candidate peptide TS1-2 as a new strategy for SRC kinase inhibitor resistance. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=107 SRC="FIGDIR/small/638389v1_ufig1.gif" ALT="Figure 1"> View larger version (42K): org.highwire.dtl.DTLVardef@1af72d0org.highwire.dtl.DTLVardef@19aedf2org.highwire.dtl.DTLVardef@7bb800org.highwire.dtl.DTLVardef@6d0d60_HPS_FORMAT_FIGEXP M_FIG C_FIG
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- STAMBPL1 activates the GRHL3/HIF1A/VEGFA axis through interaction with FOXO1 to promote angiogenesis in triple-negative breast cancer 96%
- TAK1-mediated phosphorylation of PLCE1 represses PIP2 hydrolysis to impede esophageal squamous cancer metastasis 96%
- Loss function of tumor suppressor FRMD8 confers resistance to tamoxifen therapy via a dual mechanism 95%
Similar papers in this journal
Similar papers in this journal
- Epigenetic reader ZMYND11 noncanonical function restricts HNRNPA1-mediated stress granule formation and oncogenic activity 94%
- SARS-CoV-2-Triggered Mast Cell Rapid Degranulation Induces Alveolar Epithelial Inflammation and Lung Injury 94%
- Massively parallel interrogation of human functional variants modulating cancer immunosurveillance 94%
Similar papers in this journal
- Targeting KRAS-mutant stomach/colorectal tumours by disrupting the ERK2-p53 complex 96%
- m6A Demethylase FTO Stabilizes LINK-A to Exert Oncogenic Roles via MCM3-Mediated Cell Cycle Progression and HIF-1α Activation 96%
- Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a potential therapeutic target in YAP/TAZ-active cancers 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.